ACURA PHARMACEUTICALS, INC (ACUR) Form 8-K — Jun 29, 2026
Acura Pharmaceuticals secured critical lifeline financing and deadline extensions from its majority shareholder, Abuse Deterrent Pharma (AD Pharma), to stave off immediate insolvency. The company received $400,000 in new loans during May and June 2026, bringing the total principal balance on its secured promissory note to $10,694,279 with $1,160,000 in accrued interest. In exchange for the funding, Acura amended multiple agreements to extend key deadlines from June 30, 2026, to December 31, 2026, including the maturity date of its promissory note and the FDA NDA acceptance date for its product candidate LTX-03.
Key figures
- Total Debt
- 10,694,279
- Interest Rate
- 5.25
- Accrued Interest
- 1,160,000
- New Maturity Date
- December 31, 2026
- Default Interest Rate
- 7.5
- New NDAAcceptance Date
- December 31, 2026
- Ownership Percent Schutte
- 13%
- Ownership Percent ADPharma
- 65%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.